{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_modifications_structuralModifications_residueModified in root_modifications_structuralModifications_residueModified (approximate match)
Status:
US Approved Rx
(2021)
Source:
BLA761194
(2021)
Source URL:
First approved in 2021
Source:
BLA761194
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761173
(2022)
Source URL:
First approved in 2002
Source:
BLA125031
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02923921: Phase 3 Interventional Completed Pancreatic Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sampeginterferon beta-1a [INN]
Source URL:
Class:
PROTEIN
Status:
Class:
PROTEIN
